Data / Drug companies / Par Health USA, LLC
Par Health USA, LLC: 16 products in the FDA NDC directory, labeler code 0254
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Par Health USA, LLC (labeler code 0254) lists 16 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 16 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 26, 2024.
The request: Watch Par Health USA, LLC (FDA labeler code 0254): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0254
- Products in commercial distribution
- 16
- Packages
- 16
- Finished drugs by generic name
- 10
- Prescription products
- 16
- Over the counter products
- 0
- Flagged as original packager
- 16 of 16 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- September 19, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 12 | 75% |
| Authorized generics (NDA) | 4 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 16 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Nitisinone | 3 | 6 |
| Lubiprostone | 2 | 20 |
| Posaconazole | 2 | 29 |
| Chlorzoxazone | 2 | 21 |
| Tiopronin | 2 | 8 |
| Penicillamine | 1 | 12 |
| Omega-3-acid ethyl esters | 1 | 19 |
| Alvimopan | 1 | 4 |
| Diazoxide | 1 | 3 |
| Colchicine | 1 | 34 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 6 | 37.5% |
| Capsule, gelatin coated | 2 | 12.5% |
| Suspension | 2 | 12.5% |
| Tablet | 2 | 12.5% |
| Tablet, delayed release | 2 | 12.5% |
| Tablet, film coated | 1 | 6.2% |
| Tablet, coated | 1 | 6.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tiopronin | 0254-3035 | Tablet, delayed release | Generic drugs (ANDA) | June 26, 2024 |
| Tiopronin | 0254-3034 | Tablet, delayed release | Generic drugs (ANDA) | June 26, 2024 |
| Colchicine | 0254-0460 | Capsule | Generic drugs (ANDA) | November 1, 2023 |
| Alvimopan | 0254-3012 | Capsule | Generic drugs (ANDA) | May 3, 2023 |
| Posaconazole | 0254-1016 | Suspension | Authorized generics (NDA) | March 29, 2023 |
| Chlorzoxazone | 0254-2053 | Tablet | Generic drugs (ANDA) | June 17, 2021 |
| Lubiprostone | 0254-3029 | Capsule, gelatin coated | Authorized generics (NDA) | January 1, 2021 |
| Lubiprostone | 0254-3028 | Capsule, gelatin coated | Authorized generics (NDA) | January 1, 2021 |
| Chlorzoxazone | 0254-2005 | Tablet | Generic drugs (ANDA) | November 4, 2020 |
| Diazoxide | 0254-1010 | Suspension | Generic drugs (ANDA) | July 21, 2020 |
| Penicillamine | 0254-2000 | Tablet, film coated | Generic drugs (ANDA) | January 2, 2020 |
| Nitisinone | 0254-3022 | Capsule | Generic drugs (ANDA) | October 4, 2019 |
| Nitisinone | 0254-3021 | Capsule | Generic drugs (ANDA) | October 4, 2019 |
| Nitisinone | 0254-3020 | Capsule | Generic drugs (ANDA) | October 4, 2019 |
| Posaconazole | 0254-2045 | Tablet, coated | Authorized generics (NDA) | August 30, 2019 |
| Omega-3-acid ethyl esters | 0254-3010 | Capsule | Generic drugs (ANDA) | September 19, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.